A new study led by Hartmut Geiger at the University of Ulm, Germany, and Yi Zheng and Kodandaramireddy Nalapareddy, Cincinnati Children's Hospital Medical Center (CCHMC), USA reveals that age-related changes in the gut microbiota directly impair intestinal stem cell (ISC) function and that restoring a youthful microbial environment can reverse this decline. The results were published today in Stem Cell Reports. 

The International Society for Stem Cell Research (ISSCR) today announced the upcoming release of “Charting the Translational Pathway: ISSCR Best Practices for the Development of Pluripotent Stem Cell (PSC)-Derived Therapies,” a new paper highlighting some of the most critical aspects of the ISSCR’s breakthrough interactive resource designed to transform how PSC-derived therapies are developed, evaluated, and advanced toward clinical and commercial success. The paper was published today in Stem Cell Reports.

Stem Cell Reports, the peer-reviewed, open-access journal of the International Society for Stem Cell Research (ISSCR), today announced a call for applications to serve on its editorial team, a prestigious opportunity for outstanding, early-career scientists to help shape the future of stem cell publishing. The deadline to apply is 13 March 2026.

Selected members will serve up to a three-year term beginning 1 September 2026, joining a cohort of distinguished early career researchers who will play an active role in the journal’s scientific vision and community engagement. The program is designed to provide hands-on editorial experience, mentorship, and professional visibility within the global stem cell research community.

The International Society for Stem Cell Research (ISSCR) today announced the 10 most downloaded papers of 2025 from Stem Cell Reports, its peer-reviewed, open-access journal. Together, these highly read articles reflect the extraordinary scientific range of the field – from foundational mechanisms of pluripotency and differentiation to translational advances in regenerative medicine, disease modeling, and bioethics – and underscore the journal’s role as a trusted platform for impactful stem cell science.

To date, more than 100 clinical trials with human pluripotent stem cell (hPSC)-derived products have been initiated worldwide and an increasing number of potential hPSC-derived clinical products have entered early developmental pipelines. For off-the-shelf (allogeneic) products, the identification and selection of the right hPSC line early on during this process is of utmost importance as failure to do so may delay or completely stall product development. While developers acknowledge the importance of this issue, a comprehensive, accessible listing of globally available hPSC lines to inform cell line selection for clinical use has been elusive until now.